Curio Wellness, the market-leading medicinal cannabis company in Maryland, presented a scientifically grounded, patient-focused perspective to de-schedule cannabis and have it regulated under the Food and Drug Administration’s Federal Food, Drug, and Costmetic Act.
This presentation, led by Curio chief scientific officer Edward Rudnic,and director of compliance Aaron Schwartz, was at the FDA’s public hearing on May 31.
“This is a historic moment in the regulatory journey of this vital alternative medicine that millions of Americans rely upon each day,” said Rudnic. “Curio has continually been active and engaged in promoting a proper direction for the medicinal cannabis industry by taking an approach that is deeply rooted in scientific knowledge and the needs of and safety for patients. We are hopeful this hearing will lead to the FDA taking action to allow for an appropriate balance of regulation at the Federal and State level and the increased availability of innovative medicinal cannabis products in a safe and cost-effective manner.”
Curio Wellness is at the forefront of growing, processing and dispensing medicinal cannabis through the Maryland medicinal cannabis program with a scientific and patient-centered approach.
“Our unrelenting commitment to providing safe, effective, reliable medicinal cannabis products drives the Curio team to share our knowledge and perspective to help shape public policy that benefits patients,” said CEO Michael Bronfein.
